Ask about this productRelated genes to: IKBKE antibody
- Gene:
- IKBKE NIH gene
- Name:
- inhibitor of nuclear factor kappa B kinase subunit epsilon
- Previous symbol:
- -
- Synonyms:
- IKKE, IKK-i, KIAA0151
- Chromosome:
- 1q32.1
- Locus Type:
- gene with protein product
- Date approved:
- 2002-12-02
- Date modifiied:
- 2017-01-13
Related products to: IKBKE antibody
Related articles to: IKBKE antibody
- Understanding the molecular mechanisms of host-parasite interaction remains a central challenge in fish immunology. This study presents the first transcriptomic analysis of the head kidney-a primary immune organ in teleost fish - in the Baikal omul (Coregonus migratorius) naturally infected with plerocercoids of the cestode Dibothriocephalus dendriticus. RNA-Seq data were generated and used to perform a de novo assembly of head kidney transcriptomes from infected and uninfected fish, followed by differential gene expression analysis. We identified a complex immune response characterized by the activation of pattern recognition receptors (PRRs), including C-type lectin receptors (CLRs), NOD-like receptors (NLRs), and Toll-like receptors (TLRs). KEGG pathway enrichment and DGE analysis revealed significant upregulation of pro-inflammatory signaling cascades (e.g., IKBKE, IRF5), antigen presentation components (e.g., PSMB9, MR1), as well as adapter and immunoregulatory molecules (e.g., GRAP2, TMIGD2, CD22). Concurrently, a selective down-regulation of several effector genes of both adaptive and innate immunity (e.g., IGHV, VLIG1, FCGR1A) was observed, indicating a suppression of energetically costly immune programs. GO analysis revealed significant enrichment of processes related to innate immune response, negative regulation of transcription and cell proliferation, as well as proteostasis control systems, accompanied by remodeling of the cellular component profile. These data suggest a strategy of controlled immune activation in C. migratorius, aimed at establishing long-term equilibrium with the parasite while minimizing energetic costs and immunopathology. This study expands fundamental knowledge of coregonid immunology and provides a foundation for investigating the molecular mechanisms of resistance to tissue-dwelling helminth infections. - Source: PubMed
Publication date: 2026/04/25
Mazur Olga EvgenievnaKutyrev Ivan AlexandrovichSidorova Tuyana ValeryevnaSukhanova Lubov Vasilyevna - The aggressive cancer known as pancreatic ductal adenocarcinoma (PDAC) has a remarkably poor response to treatment, especially gemcitabine (GEM). As a member of the noncanonical IκB kinase family, inhibitor of nuclear factor kappa-B kinase subunit epsilon (IKBKE) is known to regulate tumor progression in multiple cancer types. However, its functional role in modulating chemosensitivity and its impact on cell death pathways in PDAC remain unclear. - Source: PubMed
Publication date: 2026/02/16
Ren TingChen XueWang XiaozhenXu YantianShao Na - Estrogen receptor (ER) positive breast cancer is the most prevalent subtype, commonly responsive to endocrine therapies. Immune checkpoint inhibitors (ICIs) have limited efficacy in ER-positive disease, highlighting the need for the development of combination immunotherapies for these patients. We previously established that nitroso-N-methylurea-induced mammary tumors in outbred Sprague-Dawley rats mimic immune evasive mechanisms and the heterogeneity of ICI response observed in patients. We identified a "luminal growing" gene signature in ER-positive tumors, which correlated with tumor growth and immune-related differences. Here, we evaluated targeting candidates from this signature KMT5B/C and IKBKE using inhibitors A-196 and IKBKEi respectively, alongside anti-estrogen (fulvestrant) and a TGFβ blocking antibody (NIS793), both individually and in combination with αPD-L1, within this rat model. Fulvestrant emerged as the most effective treatment, inducing regression of most existing tumors and reducing on-treatment tumor burden when combined with αPD-L1. A-196, while ineffective as a monotherapy, demonstrated enhanced response when combined with αPD-L1. Comprehensive tumor profiling through polychromatic flow cytometry and single-cell RNA sequencing revealed that A-196 induced a luminal-to-basal shift in tumor epithelial cells, enhancing antigen presentation, whereas epithelial-to-mesenchymal transition was linked to fulvestrant resistance. Our findings underscore the value of the rat mammary tumor model for preclinical studies in ER-positive breast cancer and advocate for the further validation and potential clinical development of KMT5B/C inhibitors to enhance the efficacy and broaden the applicability of ICI therapy in cancer patients. - Source: PubMed
Publication date: 2026/02/05
Rojas-Jimenez ErnestoBui Triet MYan PengzeLi ZheqiSeehawer MarcoNishida JunFoidart PierreFreeman Gordon JPolyak Kornelia - Senecavirus A (SVA) is an emerging picornavirus causing vesicular disease indistinguishable from foot-and-mouth disease virus (FMDV). So far, there are no commercial vaccines and effective therapeutic drugs against SVA infection in China. Here, a library of 112 compounds were screened, and we found that phorbol myristate acetate plays an antagonistic role in the early stage of SVA infection. And phorbol 12-myristate 13-acetate (PMA) upregulates the expression of IKBKE, and activates IFN pathway and NF-κB signal. However, the PMA-mediated detrimental effect on SVA is reversed in IKBKE-deficient cells or when the NF-κB pathway blocked by BAY-117082, implying that IKBKE is the target for the antiviral effect of PMA. Additionally, PMA possesses antiviral effect on multiple RNA viruses, including porcine epidemic diarrhea virus (PEDV), porcine reproductive and respiratory syndrome virus (PRRSV), and encephalomyocarditis virus (EMCV). Overall, our findings offer that PMA inhibits SVA replication by activating IKBKE-mediated IFN pathway and NF-κB signal. And it might be a promising candidate for further broad-spectrum therapeutic development. - Source: PubMed
Publication date: 2026/01/31
Yan JunfangGao YanniGuo ChengyiDong YubeiJiang PingBai Juan - Individuals exhibit considerable heterogeneity in vaccine-induced antibody responses, yet commonly used binary classifications may overlook intermediate patterns. More nuanced grouping could better capture inter-individual differences. Here, we analyzed longitudinal neutralizing antibody (NAb) trajectories in 73 adults after inactivated SARS-CoV-2 vaccination. Unsupervised analysis identified three phenotypes: Low-Delayed Responders (LR), with a modest, delayed NAb rise to day 30; Rapid-Stabilizing Responders (RS), peaking at day 7 and plateauing thereafter; and Continuous Increase Responders (CI), exhibiting sustained increases. Between days 0 and 7, these groups diverged in immune activation: LR showed limited pathway activation or cell shifts; RS exhibited early innate activation with reduced dendritic cells; CI mounted innate and adaptive responses with increased naive B cells. These differences culminated at day 7, when CI exhibited enhanced antigen presentation and Th1-related pathways, accompanied by higher IFN-γ and IL-2 T cell responses. CI also showed post-transcriptional regulation of innate signaling, including HLA-F/H splicing, 3'UTR shortening in IKBKE and HRAS, and biased IGHV4-59-IGHJ4 usage. Finally, we developed a baseline gene model accurately predicting LR individuals. Our work refines responder classification and provides molecular insights into antibody heterogeneity, laying groundwork for early stratification and personalized vaccination. - Source: PubMed
Publication date: 2026/01/30
Wu QingqinHu HuajieQin LiuyuMa XupuChen BohaoLi XuanChen YanliXing LeiYang MeiLi ChunmeiZhang Zijie ScottPan XuerongCheng Rui